4.7 Review

Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies

期刊

ALIMENTARY PHARMACOLOGY & THERAPEUTICS
卷 32, 期 6, 页码 720-737

出版社

WILEY
DOI: 10.1111/j.1365-2036.2010.04406.x

关键词

-

资金

  1. Houston VA HSR&D Center of Excellence [HFP90-020]
  2. AstraZeneca
  3. AstraZeneca R&D, Molndal, Sweden

向作者/读者索取更多资源

P>Background Persistent gastro-oesophageal reflux disease (GERD) symptoms can occur despite proton pump inhibitor (PPI) therapy. Aim To assess the prevalence and potential determinants of persistent GERD symptoms in primary care and community-based studies. Methods Studies were identified by systematic PubMed and Embase searches; pooled prevalence data are shown as sample-size weighted means and 95% confidence intervals. Results Nineteen studies in individuals with GERD taking a PPI were included. In interventional, nonrandomized primary care trials, the prevalence of persistent troublesome heartburn and regurgitation was 17% (6-28%) and 28% (26-30%) respectively; in randomized trials, it was 32% (25-39%) and 28% (26-30%), respectively. In observational primary care and community-based studies, 45% (30-60%) of participants reported persistent GERD symptoms. Overall, persistent GERD symptoms despite PPI treatment were more likely in studies with a higher proportion of female participants [> 60% vs. < 50%, risk ratio (RR): 3.66; P < 0.001], but less likely in studies from Europe than in those from the USA (RR: 0.71; P < 0.001), and were associated with decreased psychological and physical well-being. Conclusions Persistent GERD symptoms despite PPI treatment are common in the primary care and community setting. Alternative approaches to management are required.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据